NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BioLineRx Ltd. (BLRX) Stock Analysis

BioLineRx Ltd. (BLRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BLRX

$2.11

−$0.10 (−4.72%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLRX with… →

BLRX Key Statistics

As of Oct 21, 2026
Trading
Open
$2.19
Previous Close
$2.21
Day's Range
1.96–2.19
52-Week Range
1.95–4.07
Volume
1.82K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$10.21M
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.33
EPS (ttm)Profit attributable to each share over the last twelve months.
0.00
Financials (FY)
Revenue (FY)
$1.18M−95.92%
Net Income (FY)
−$1.18M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.98M
1-Year Return
−42.19%
Dividend and dates
Earnings Date
November 23, 2026estimated
Avg Volume
16.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BLRX closed at $2.11, −42.19% over 1 year.

BioLineRx Ltd. (BLRX) has a market capitalization of $10.21M.

In fiscal 2025, BLRX reported revenue of $1.18M.

BLRX Stock Return by Calendar Year

BioLineRx Ltd. (BLRX) 10-year return: what $10,000 became

1 year
$10,000 $5,781
−42.19%
5 years
$10,000 $174
−98.26%
10 years
$10,000 $34
−99.66%

If you had invested $10,000 in BioLineRx Ltd. (BLRX) 10 years ago, at the close on October 21, 2016, it would have been worth $34 at the close on October 21, 2026: −99.66% in total, −43.39% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−23.83%
2025−67.02%
2024−86.62%
2023+166.10%
2022−71.08%
2021−19.05%
2020+12.00%
2019−65.91%
2018−59.63%
2017+18.48%
2016 (partial year)+13.58%

As of October 21, 2026.

BLRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.18M−$1.18M−99.6%
2024$28.94M−$9.22M−31.9%
2023$4.80M−$60.61M−1,262.8%
2022$0.00−$24.95M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.18M$950.00K−$10.29M−$1.18M−99.6%
2024$28.94M$19.68M−$19.15M−$9.22M−31.9%
2023$4.80M$1.11M−$42.99M−$60.61M−1,262.8%
2022$0.00$0.00−$29.16M−$24.95M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BLRX Valuation vs Biotechnology Median

Median of 608 stocks
MetricBLRXBiotechnology medianvs median
P/S ratio7.3313.3045% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioLineRx Ltd. (BLRX) carries a market capitalisation of $10.21M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 20 employees.

The most recent close on file for BLRX is $2.11, dated October 21, 2026. That is −$0.10 (−4.72%) against the previous close. Over the past 52 weeks the price has ranged from $1.95 to $4.07. The latest close sits 8.48% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.18M. That is −95.92% against the prior fiscal year, when revenue was $28.94M. The same year closed with a net loss of $1.18M. Earnings per share on a trailing basis come to 0.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.18M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The price-to-sales ratio is 7.33. On price-to-sales that is 44.87% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −42.19%. Across 10 years the annualized return works out at −43.39%. Beta against the wider market is reported at 0.7. Annualized volatility over the trailing 10 years is 81.14%.

Growth & Income

The record shows no dividend for BLRX.

The strongest complete calendar year on file is 2023 at +166.10%; the weakest is 2024 at −86.62%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −23.83%.

Peer Comparison

BioLineRx Ltd. (BLRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioLineRx Ltd. BLRX $10.21M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BioLineRx Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BioLineRx Ltd.

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Visit website →